Anti-PD-L1 antibodies have shown significant improvement in liver injury morphology in CLP mice by reducing glutamic pyruvic transaminase (ALT) and glutamic oxaloacetic transaminase (AST) release, as well as decreasing TNF-α, interleukin (IL)-6, and IL-10 mRNA levels in the liver after sepsis (143). This evidence concerns the gene TNF and Sepsis.